Abstract Pneumocystis jiroveci pneumonia in non-HIV patients is infrequent and characterized by atypical presentations and increased severity. Although hematogenous dissemination from the lungs can lead to extrapulmonary infections, isolation of oocysts from blood in human subjects has not been documented. We report a case of P. jiroveci pneumonia with persistent isolation of oocysts from blood and positivity of P. jiroveci polymerase chain reaction. The patient presented with bilateral diffuse pulmonary nodules and received prolonged treatment with trimethoprim/sulfamethoxazole.
A 58-year-old male patient with idiopathic membranous-proliferative glomerulonephritis treated with bolus corticosteroids, cyclophosphamide, and rituximab was admitted to the hospital with complaints of fever (T max 101°F) and progressive dyspnea for 1 week. Absolute CD4? T cell count was 90 (11%) cells/mm 3 . A chest CT scan showed fine reticular and ground-glass opacities along with diffused bilateral lung nodules. Pneumocystis jiroveci oocysts were detected in bronchoalveolar lavage fluid by immunofluorescence staining. Immunosuppressive therapy was discontinued, and the patient was treated with trimethoprim/sulfamethoxazole (TMP/SMX) for 21 days showing improvement of respiratory symptoms. Ten days after treatment discontinuation, however, he presented with fever (T 101.4°F) and high serum levels of (1-3)-b-D-Glucan (BDG, 432 pg/ml). Peripheral blood smear showed evidence of P. jiroveci oocysts (Fig. 1) confirmed by real-time polymerase chain reaction (RT-PCR). The chest CT scan showed persistence of a diffuse nodular pattern (Fig. 2) . The patient was started on IV TMP/SMX in combination with caspofungin for 14 days and subsequently switched to oral TMP/SMX. Despite progressive radiological improvement and normalization of BDG after 6 weeks of treatment, persistence of P. jiroveci oocysts was confirmed in blood smears. Therapeutic drug monitoring of TMP/SMX was within normal ranges. Due to an increase in liver enzymes, a liver biopsy was performed and resulted negative for P. jiroveci. No other apparent localizations of infection were evident. A progressive reduction in the number of P. jiroveci oocysts in blood along with clinical and radiological improvement was reported over the following months. After 10 months of TMP/SMX treatment, we observed RT-PCR and blood smears negativization, along with significant reduction in the lung nodules and CD4? T lymphocyte count [ 500 cells/mm 3 . No defects in lymphocyte populations were detected except for a low CD4:CD8 ratio. The patient was maintained on TMP/SMX thrice weekly for 6 months followed by treatment discontinuation. As of the writing of this report, the patient is well and free of relapse 30 months after initial presentation, with persistent blood smear negativization.
In our case, persistence of P. jiroveci oocysts was detected despite prolonged antimicrobial therapy. Persistent blood positivity for P. jiroveci oocysts may have developed as part of a disseminated infection, with seeding extending from a lung focus, which can eventually calcify in a punctate fashion.
Some important observations can be made based on this case. First, recognition of P. jiroveci infection (PJI) is important since increased severity is reported in disseminated infections, especially among non-HIV patients who may present with atypical forms of the disease. Specifically, while the spread of P. jiroveci has been reported in animal models in association with destruction of lung tissue, extrapulmonary pneumocystosis and persistent PJI are infrequent in humans. To our knowledge, detection of P. jiroveci oocysts from blood in human subjects has not been previously reported. Second, TMP/SMX remains the mainstay of P. jiroveci treatment, although antimicrobial resistance should be considered when there is no clinical recovery. We did not perform TMP-SMX susceptibility testing since clinical and radiological improvements were observed during treatment.
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